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Abstract
Objective: Apoptosis is increased in sepsis. Cytokeratin 18 (CK-18), a protein of the intermediate filament group present in
most epithelial and parenchymal cells, is cleaved by the action of caspases and released into the blood as caspase-cleaved
CK (CCCK)-18 during apoptosis. Circulating levels of CCCK-18 have scarcely been explored in septic patients. In one study
with 101 severe septic patients, the authors reported higher serum CCCK-18 levels in non-survivors than in survivors;
however, the sample size was too small to demonstrate an association between serum CCCK-18 levels and early mortality
and whether they could be used as a biomarker to predict outcomes in septic patients. Thus, these were the objectives of
this study with a large series of patients.
Methods: We performed a prospective, multicenter, observational study in six Spanish Intensive Care Units with 224 severe
septic patients. Blood samples were collected at the time that severe sepsis was diagnosed to determine serum levels of
CCCK-18, tumor necrosis factor (TNF)-alpha, interleukin (IL)-6 and IL-10. The end point was 30-day mortality.
Results: Non-surviving patients (n = 80) showed higher serum CCCK-18 levels (P,0.001) than survivors (n = 144). Multiple
logistic regression analysis showed that serum CCCK-18 levels.391 u/L were associated with 30-day survival (Odds
ratio = 2.687; 95% confidence interval = 1.449–4.983; P = 0.002), controlling for SOFA score, serum lactic acid levels and age.
Kaplan-Meier survival analysis showed that the risk of death in septic patients with serum CCCK-18 levels .391 u/L was
higher than in patients with lower values (Hazard Ratio = 3.1; 95% CI = 1.96–4.84; P,0.001). Serum CCCK-18 levels were
positively associated with serum levels of IL-6 and lactic acid, and with SOFA and APACHE scores.
Conclusions: The major novel finding of our study, the largest cohort of septic patients providing data on circulating CCCK-
18 levels, was that serum CCCK-18 levels are associated with mortality in severe septic patients.
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Introduction
Severe sepsis is a common, expensive, and frequently fatal
condition [1,2]. The apoptotic process is one in which cells are
actively eliminated via a programmed pathway during morpho-
genesis, tissue remodeling, and the resolution of the immune
response. Apoptosis is increased in sepsis and could contribute to
multiple organ failure and death of septic patients [3–6].
Cytokeratin 18 (CK-18) is a protein of the intermediate filament
group present in most epithelial and parenchymal cells [7]. During
apoptosis CK-18 is cleaved at various sites by the action of
caspases, and the resulting fragments are released into the blood
[8]. Full-length CK-18 is released into the blood plasma during
necrosis, and CK-18 fragments are released during apoptosis.
Determination of CK-18 fragments can be carried out by using a
monoclonal antibody (M30) that recognizes caspase-cleaved CK-
18 fragments, containing the CK-18 Asp 396 neoepitope, without
detecting native or intact CK-18 [9,10].
Circulating levels of caspase-cleaved CK (CCCK)-18 has been
studied in patients with liver [11–14], tumoral [15,16] and graft-
versus-host [17] diseases. However, it has scarcely been explored
in septic patients [18–20]. These studies found higher blood
CCCK- 18 levels in septic patients than in healthy controls
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[18–20]. In one study with 101 severe septic patients, higher serum
CCCK-18 levels were found in non-survivors than in survivors
[20]; however, the sample size was too small to demonstrate an
association between serum CCCK-18 levels and early mortality
and whether they could be used as a biomarker to predict
outcomes in septic patients. Thus, the objective of this study was to
determine whether there is an association between serum CCCK-
18 levels and mortality and whether they could be used as a
biomarker to predict outcomes in a large series of patients.
Methods
Design and Subjects
A prospective, multicenter, observational study was carried out
in six Spanish Intensive Care Units between 2008–2009. The
study was approved by the Institutional Ethic Review Boards of
the six participating hospitals: Hospital Universitario de Canarias
(La Laguna. Tenerife. Spain), Hospital Universitario Nuestra
Señora de Candelaria (Santa Cruz de Tenerife. Spain), Hospital
Universitario Dr. Negrı́n (Las Palmas de Gran Canaria. Spain),
Hospital Clı́nico Universitario de Valencia (Valencia. Spain),
Hospital San Jorge (Huesca. Spain) and Hospital Insular (Las
Palmas de Gran Canaria. Spain). Written informed consent from
the patients or from their family members was obtained.
A total of 224 patients with severe sepsis were included. The
inclusion criteria used for severe sepsis were those defined by the
International Sepsis Definitions Conference [21]. The exclusion
criteria were: age ,18 years, pregnancy, lactation, human
immunodeficiency virus (HIV), white blood cell count ,1,000/
ml, solid or hematological tumor, or immunosuppressive, steroid or
radiation therapy.
Variables recorded
The following variables were recorded for each patient: sex, age,
diabetes mellitus, chronic renal failure defined as glomerular
filtration rate (GFR) ,60 ml/min per 1.73 m2, chronic obstructive
pulmonary disease (COPD), site of infection, microorganism
responsible, bloodstream infection, empiric antimicrobial treat-
ment, pressure of arterial oxygen/fraction inspired of oxygen
(PaO2/FIO2), creatinine, bilirubin, leukocytes, lactic acid, plate-
lets, international normalized ratio (INR), activated partial
thromboplastin time (aPTT), Acute Physiology and Chronic
Health Evaluation II (APACHE II) score [22] and Sepsis-related
Organ Failure Assessment [SOFA] score [23].
End-point
The end-point of the study was 30-day mortality.
Blood samples
Blood samples from 224 patients were collected at the time
severe sepsis was diagnosed. Serum was allowed to clot for 10
minutes at room temperature, then centrifuged at 1000 6g for 15
minutes and the supernatant was immediately stored in aliquot at
280uC to the end of the recruitment process. All determinations
were performed by laboratory technicians blinded to all clinical
data. Assays were performed at the Laboratory Department of the
Hospital Universitario de Canarias (La Laguna, Santa Cruz de
Tenerife, Spain).
Serum CCCK-18 analysis
CCCK-18 levels were measured in serum by enzyme-linked
immunosorbent assay (ELISA) using M30 Apoptosense ELISA,
PEVIVA AB (Bromma, Sweden), lot PE-0133. The M30 antibody
recognises a neo-epitope exposed after caspase cleavage of K18
after the aspartic acid residue 396. M30 Apoptosense ELISA
measures detects soluble caspase-cleaved K18 (ccK18) fragments
containing the K18Asp396 neo-epitope. M30-antigen levels are
expressed as U/l. The intra- and inter-assay coefficients of
variation (CV) were ,10%. The detection limit for the assay
was 25 U/L.
Serum levels of tumor necrosis factor (TNF)-alpha,
interleukin (IL)-6 and IL-10 analysis
TNF-alpha, IL-6 and IL-10 were measured in serum by solid-
phase chemiluminescent immunometric assays (Immulite, Siemens
Healthcare Diagnostics Products, Llanberis, United Kingdom).
The intra-assay CV were 3.6%, 6.2%, and 9.9%, respectively. The
interassay CV were 6.5%, 7.5%, and 9.9%, respectively. The
detection limits for the assays were 1.7 pg/ml, 2.0 pg/ml and
1 pg/ml respectively.
Statistical Methods
Continuous variables are reported as medians and interquartile
ranges. Categorical variables are reported as frequencies and
percentages. Comparisons of continuous variables between groups
were carried out using Mann-Whitney U test. Comparisons
between groups for categorical variables were carried out with chi-
square test. We plotted a receiver operating characteristic (ROC)
curve using survival at 30 days as the classification variable, and
serum CCCK-18 levels as the prognostic variable. Analysis of
survival at 30 days with Kaplan-Meier method curve and
comparisons by log-rank test were carried out using serum
CCCK-18 levels lower/higher than 391 u/L as the independent
variable, and survival at 30 days as the dependent variable. We
used dot-plot to represent serum caspase-cleaved citokeratin
(CCCK)-18 levels in 30-day surviving and non-surviving septic
patients. Multiple logistic regression analysis was carried out to test
the independent contribution of serum CCCK-18 levels higher
than 391 u/L on the prediction of 30-day mortality, controlling
for SOFA score, lactic acid levels and age. Odds ratio and 95%
confidence intervals (CI) were calculated as measures of the
clinical impact of the predictor variables. Wald test was calculated
for each variable included in the regression model. We used
Spearman’s rank correlation coefficient to determine the associ-
ation between continuous variables. A P value of less than 0.05 was
considered statistically significant. Statistical analyses were per-
formed with SPSS 17.0 (SPSS Inc., Chicago, IL, USA) and NCSS
2000 (Kaysville, Utah).
Results
Table 1 shows the comparison of demographic and clinical
parameters between surviving (n = 144) and non-surviving (n = 80)
septic patients. We found that non-surviving septic patients
showed higher age, creatinine, lactic acid, INR, aPTT, SOFA
and APACHE-II scores, and lower platelet count than surviving
patients. In addition, non-surviving septic patients showed higher
serum levels of CCCK-18 (P,0.001), IL-6 (P = 0.001) and IL-10
(P = 0.002) than survivors. No differences were observed regarding
sex, diabetes mellitus, chronic renal failure, COPD, ischemic heart
disease, site of infection, microorganism responsible, bloodstream
infection, antimicrobial treatment and serum levels of TNF-a.
Multiple logistic regression analysis showed that serum CCCK-
18 levels.391 u/L were associated with 30-day survival (Odds
ratio = 2.687; 95% CI = 1.449–4.983; P = 0.002), controlling for
SOFA score, serum lactic acid levels and age (Table 2).
Serum Cytokeratin-18 Levels in Sepsis
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Receiver Operating Characteristic (ROC) analysis showed that
the area under curve of serum CCCK-18 levels to predict 30-day
survival was 0.71 (95% CI = 0.64–0.76; P,0.001) (Figure 1).
Kaplan-Meier survival analysis showed that the risk of death in
septic patients with serum CCCK-18 levels above 391 u/L was
higher than in patients with lower values (Hazard Ratio = 3.1;
95% CI = 1.96–4.84; P,0.001) (Figure 2).
Table 1. Patients’demographic and clinical characteristics.
Survival Non-survival p-value
(n = 144) (n = 80)
Sex male – n (%) 93 (64.6) 54 (67.5) 0.77
Age - median years (p 25–75) 55 (44–66) 64 (56–74) ,0.001
Diabetes mellitus – n (%) 40 (27.8) 31 (38.8) 0.10
Chronic renal failure – n (%) 8 (5.6) 8 (10.0) 0.28
COPD – n (%) 15 (10.4) 12 (15.0) 0.39
Ischemic heart disease - n (%) 13 (9.0) 5 (6.3) 0.61
Site of infection 0.68
Respiratory - n (%) 81 (56.3) 48 (60.0)
Abdominal - n (%) 38 (26.4) 21 (26.3)
Neurological 3 (2.1) 0
Urinary - n (%) 8 (5.6) 4 (5.0)
Skin - n (%) 8 (5.6) 3 (3.8)
Endocarditis - n (%) 6 (4.2) 4 (5.0)
Microorganism responsibles
Unknwon - n (% 75 (52.1) 43 (53.8) 0.89
Gram-positive- n (%) 33 (22.9) 21 (26.3) 0.63
Gram-negative- n (%) 35 (24.3) 16 (20.0) 0.51
Fungii- n (%) 4 (2.8) 4 (5.0) 0.46
Anaerobe- n (%) 1 (0.7) 1 (1.3) 0.99
Bloodstream infection - n (%) 22 (15.3) 11 (13.8) 0.85
Empiric antimicrobial treatment adequate 0.96
Unknown due to negative cultures- n (%) 75 (52.1) 43 (53.8)
Adequate - n (%) 58 (40.3) 30 (37.5)
Unknown due to antigenuria diagnosis-n(%) 4 (2.8) 3 (3.8)
Inadequate- n (%) 7 (4.9) 4 (5.0)
Betalactamic plus aminoglycoside - n (%) (%)aminoglycoside- n (%) 29 (20.1) 20 (25.0) 0.40
Betalactamic plus quinolone - n (%) 79 (54.9) 43 (53.8) 0.89
Pa02/FI02 ratio - median (p 25–75) 170 (113–262) 180 (100–244) 0.38
Creatinine (mg/dl) - median (p 25–75) 1.20 (0.80–1.95) 1.50 (0.90–2.75) 0.02
Bilirubin (mg/dl) - median (p 25–75) 0.90 (0.44–1.53) 1.00 (0.47–2.44) 0.60
Leukocytes (cells/mm3) - median*103 (p 25–75) 15.2 (10.0–20.7) 15.3 (9.4–21.3) 0.88
Lactic acid (mmol/L) - median (p 25–75) 1.80 (1.05–3.50) 3.50 (1.45–5.95) ,0.001
Platelets (cells/mm3) - median*103 (p 25–75) 192 (130–273) 124 (76–222) ,0.001
INR - median (p 25–75) 1.27 (1.10–1.53) 1.42 (1.16–1.90) 0.01
aPTT (seconds) - median (p 25–75) 32 (28–42) 38 (29–46) 0.01
SOFA score - median (p 25–75) 9 (7–11) 11 (9–15) ,0.001
APACHE-II score - median (p 25–75) 18 (14–22) 23 (18–28) ,0.001
CCCK-18 (U/l) - median (p 25–75) 311 (230–443) 453 (311–711) ,0.001
TNF-alpha - median pg/ml (percentile 25–75) 31.8 (20.0–51.2) 39.4 (18.7–76.8) 0.29
Interleukin-6 - median pg/ml (percentile 25–75) 104 (42–578) 504 (58–1000) 0.001
Interleukin-10 median pg/ml (percentile 25–75) 10.4 (5.7–38.0) 52.0 (8.4–162.5) 0.002
COPD = Chronic Obstructive Pulmonary Disease; PaO2/FIO2 = pressure of arterial oxygen/fraction inspired oxygen; aPTT = Activated partial thromboplastin time;
INR = International normalized ratio; Acute Physiology and Chronic Health Evaluation (APACHE)-II score; SOFA = Sepsis-related Organ Failure Assessment;
CCCK = caspase-cleaved citokeratin; TNF = tumor necrosis factor (TNF)-alpha; data are presented as number (percentage) or median (interquartile range).
doi:10.1371/journal.pone.0109618.t001
Serum Cytokeratin-18 Levels in Sepsis
PLOS ONE | www.plosone.org 3 October 2014 | Volume 9 | Issue 10 | e109618
We ploted serum caspase-cleaved citokeratin (CCCK)-18 levels
in 30-day surviving and non-surviving septic patients (Figure 3).
We found that survival patients at 30 days with serum CCCK-
18 levels above 391 u/L at the time that severe sepsis was
diagnosed showed higher ICU stay that patients with lower values
[24 (12–46) vs 15 (7–31) days; p = 0.04].
Serum CCCK-18 levels were positively associated with serum
levels of IL-6 and lactic acid, and with SOFA and APACHE scores
(Table 3).
We found that patients with liver dysfunction showed higher
serum CCCK-18 levels than patients without it [413 (278–626) vs
327 (251–500) U/l; p = 0.01], and that patients with kidney
dysfunction showed higher serum CCCK-18 levels than patients
without it [398 (280–628) vs 318 (237–450) U/l; p,0.001].
Discussion
To our knowledge, this study includes the largest series
providing data on circulating CCCK-18 levels in septic patients.
The major novel findings of our study were that serum CCCK-18
levels are associated with mortality and could be used as a
biomarker to predict outcomes in septic patients.
We found higher serum CCCK-18 levels in non-surviving septic
patients than in survivors. These findings are in consonance with
those of a study by Hofer et al. with 101 severe septic [20];
however, the sample size in that study was too small to
demonstrate whether serum CCCK-18 levels are associated with
mortality. The greater sample size of our study enabled us to carry
out multiple regression analysis and showed, for the first time, that
serum CK-18 levels are associated with mortality in septic patients.
The advantage of measuring serum CCCK-18 levels to predict
Figure 1. Receiver operation characteristic analysis using serum caspase-cleaved cytokeratin (CCCK)-18 levels as predictor of
mortality at 30 days.
doi:10.1371/journal.pone.0109618.g001
Table 2. Multiple logistic regression analyses to predict survival at 30 days.
Wald test Odds Ratio 95% Confidence Interval P-value
Serum CCCK-18 levels.391 u/L 9.83 2.687 1.449–4.983 0.002
SOFA score 6.45 1.125 1.027–1.232 0.01
Serum lactic acid levels (mmol/L) 2.98 1.108 0.986–1.246 0.08
Age (years) 5.61 1.027 1.005–1.050 0.02
CCCK = caspase-cleaved citokeratin; SOFA = Sepsis-related Organ Failure Assessment.
doi:10.1371/journal.pone.0109618.t002
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survival at 30 days compared with SOFA score underlies in a
higher predictive value measured with the Wald test.
Another interesting new finding of our study, according to the
results of ROC curve analysis, was that serum CK-18 levels could
be used as a biomarker to predict outcomes in septic patients.
Hofer et al. found an association between serum CCCK-18 and
lactate levels [20]. In our study, we also found this association. In
addition, we found an association between serum CCCK-18 levels
and other measures of sepsis severity, such as SOFA and
APACHE-II scores for the first time.
Taken together, these results indicate that serum CCCK-18
levels may be of great pathophysiological significance in septic
patients and that apoptosis could contribute to multiple organ
failure and death of septic patients. Apoptotic cell death occurs
primarily through three different pathways: the extrinsic death
receptor pathway (type I cells), the intrinsic (mitochondrial)
pathway (type II cells) and the endoplasmic reticulum or stress-
induced pathway [3–6]. In type I cells, apoptosis is initiated by the
activation of a surface death receptor of tumor necrosis factor
receptor superfamily (TNFRSF) by its cognate death ligand
(TNFSF). In type II cells, the initiation of apoptosis can be
activated by cytokines such as interleukin (IL)-1 and IL-6, oxygen
free radicals and nitric oxide (NO); and could be reduced by the
activation of anti-apoptotic members of the Bcl-2 family by means
of IL-10. The death signal is transduced, then a cascade of
caspases leads to cell death. During this caspase activation, CK-18
is cleaved and CCCK-18 is released into the blood. In our study,
we found an association between serum CCCK-18 and Il-6 levels;
however, we did not find an association between serum CCCK-18
and TNF-alpha and IL-10 levels.
From a therapeutic perspective, the development of modulators
of apoptotic activity could be used as a new class of drugs for the
treatment of severe sepsis. In septic rats, the administration of
modulators of apoptotic activity has been found to reduce
apoptosis and increase survival rates [24–26].
The strengths of our study are that it was a multicenter study
(which increases the external applicability of results to other
similar units) and the large sample size (which allowed us to carry
out multiple logistic regression analysis to determine the associ-
ation between serum CCCK-18 levels and mortality). However,
some limitations of our study should be recognized. First, no
analysis of serum CCCK-18 levels during follow-up was
performed. Second, measuring other inducers of apoptosis and
compounds of apoptosis would be desirable in order to better
evaluate the relationship with these aspects. Third, we did not
determine serum CCCK-18 levels in control groups, such as
patients with non-infectious systemic inflammatory response
syndrome, and this would have been interesting to assess whether
CCCK-18 measurements might be useful for early diagnosis of
sepsis. Four, the determination of total serum CCCK-18 levels by
M65 ELISA or M65 EpiDeath ELISA would have been
interesting in order to quantify the leading mode of cell death
(apoptosis or necrosis).
Conclusions
The major novel finding of our study, the largest cohort of septic
patients providing data on circulating CCCK-18 levels, was that
serum CCCK-18 levels are associated with mortality in severe
septic patients.
Figure 2. Survival curves at 30 days using serum caspase-
cleaved citokeratin (CCCK)-18 levels higher or lower than
391 u/L.
doi:10.1371/journal.pone.0109618.g002
Figure 3. Dot-plot of serum caspase-cleaved citokeratin
(CCCK)-18 levels in 30-day surviving and non-surviving septic
patients.
doi:10.1371/journal.pone.0109618.g003
Table 3. Correlation of serum caspase-cleaved citokeratin
(CCCK)-18 levels with serum levels of TNF-a, interleukin-6,






Lactic acid (mmol/L) 0.20 0.003
SOFA score 0.27 ,0.001
APACHE score 0.30 ,0.001
TNF = tumor necrosis factor; SOFA = Sepsis-related Organ Failure Assessment
score; APACHE = Acute Physiology and Chronic Health Evaluation (APACHE)-II
score; rho = Spearman’s rank correlation coefficient.
doi:10.1371/journal.pone.0109618.t003
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